International variation in the use of evidence-based medicines for acute coronary syndromesSustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trialStatin use and sex-specific stroke outcomes in patients with vascular diseaseFrequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.Sex differences in mortality following acute coronary syndromes.Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis.Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction.Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy.Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.Cost Effectiveness of Early Discharge after Uncomplicated Acute Myocardial InfarctionComparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary interventionIntroduction
P50
Q28166289-9E9CB818-D207-4553-BA05-37124A1E2B36Q28195519-03375659-DDCD-4FFD-850B-C78CD4DB036FQ28196876-DA761730-1D5A-4296-8E98-BD2FE7EDCA38Q28196878-FE0FCEB7-6C4F-434B-9946-D8D89DD0E314Q35636434-98142BBF-F43A-4331-8AEC-12963A38AAC5Q37424804-1787A114-9DD7-42EF-B549-D1FE32BA6937Q39796248-5821AC16-7DF1-4BD9-8E59-586E42A55DBAQ40409225-9BDAC561-6B9D-4013-B10B-623A22CD37AFQ40414727-6E5FBD70-EE86-406F-BD03-115376AB04AAQ40615288-D887343C-6D51-4B64-962B-410A13449F20Q42624671-18C164E1-12B0-4A43-A73B-7E1EBAB0D48DQ42652089-D1E45C8B-097A-4973-834B-FB807EBD1897Q42687183-0E297105-7FFC-4AF7-AA84-A8746695999CQ43832639-D190054B-0BE6-4791-B8CB-D7D264D8CBCCQ44064957-30E4D511-DC54-4185-B86B-5F3021DA27D4Q45200529-CA6755E1-30EF-4F4C-A36F-C571632D0A9DQ46245889-26424AF2-01C8-4F79-9CCF-B281EAE7DA91Q46861395-A90746D5-7880-49C3-A06A-179B407EE720Q47381371-1968A8FF-D56B-4E3C-8FD9-075BCC91E081Q51032392-2ED1F07D-2949-4049-A1D3-995BD818D98DQ53870809-618CCB49-DC44-474C-AB35-DCE0F0C79FF0Q56928572-02920BFA-230D-4201-A2D2-D8BC95F0ED0DQ56944673-44946C0B-C440-42BE-90DE-FE118A8D2A46Q56945170-BBFB296E-9B82-457C-A6CD-EDC66FCE9825
P50
description
cardioloog uit Nieuw-Zeeland
@nl
cardiólogu neozelandés
@ast
neuseeländischer Mediziner
@de
name
Harvey D. White
@ast
Harvey D. White
@de
Harvey D. White
@en
Harvey D. White
@es
Harvey D. White
@fr
Harvey D. White
@nl
Harvey D. White
@sl
type
label
Harvey D. White
@ast
Harvey D. White
@de
Harvey D. White
@en
Harvey D. White
@es
Harvey D. White
@fr
Harvey D. White
@nl
Harvey D. White
@sl
prefLabel
Harvey D. White
@ast
Harvey D. White
@de
Harvey D. White
@en
Harvey D. White
@es
Harvey D. White
@fr
Harvey D. White
@nl
Harvey D. White
@sl
P214
P106
P21
P214
P27
P31
P569
2000-01-01T00:00:00Z
P734
P735
P7859
lccn-no2011083162